{"id":1644,"date":"2019-01-28T22:58:39","date_gmt":"2019-01-28T22:58:39","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/information-related-to-the-voluntary-recall-of-infants-ibuprofen-concentrated-oral-suspension-usp-nsaid-50-mg-per-1-25-ml\/"},"modified":"2024-06-03T12:48:39","modified_gmt":"2024-06-03T11:48:39","slug":"information-related-to-the-voluntary-recall-of-infants-ibuprofen-concentrated-oral-suspension-usp-nsaid-50-mg-per-1-25-ml","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/information-related-to-the-voluntary-recall-of-infants-ibuprofen-concentrated-oral-suspension-usp-nsaid-50-mg-per-1-25-ml\/","title":{"rendered":"Information Related to the Voluntary Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]Published on January 29, 2019<\/p>\n

Tris Pharma recently issued an expansion of the voluntary recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL <\/strong>and an associated press release to include 3 lots (4718; 00717005A, 00717006A) in addition to the lots (00717009A; 00717015A; 00717024A)previously announced\u00a0 in December 2018.\u00a0 The reason for the recall was a potential higher concentration of Ibuprofen of less than 10% above the specified limit in some bottles from these three batches. Safety issues or toxicity is generally accepted to be a concern in infants at doses in excess of 700% of the recommended dose.1<\/sup><\/p>\n

Tris is committed to ensuring that all of our manufactured products are safe and effective. Please be advised of the following:<\/p>\n